{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:26:33Z","timestamp":1792207593572,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100025190","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jtct.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T12:04:03Z","timestamp":1736165043000},"page":"159-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Reduced Chimeric Antigen Receptor T Cell Expansion Postinfusion Is Associated with Poor Survival in Patients with Large B Cell Lymphoma after Two or More Therapies"],"prefix":"10.1016","volume":"31","author":[{"given":"Edward","family":"Abadir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Wayte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Reaiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Debosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Favaloro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Aklilu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Dunkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"McCulloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-291X","authenticated-orcid":false,"given":"Stephen","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2975-807X","authenticated-orcid":false,"given":"John E.J.","family":"Rasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Vanguru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Joy","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.01.001_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.855730","article-title":"Best treatment option for patients with refractory aggressive B-cell lymphoma in the CAR-T cell era: real-world evidence from GELTAMO\/GETH Spanish groups","volume":"13","author":"Bastos-Oreiro","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2025.01.001_bib0002","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.01.001_bib0003","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience","volume":"198","author":"Kuhnl","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2025.01.001_bib0004","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2025.01.001_bib0005","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","article-title":"Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy","volume":"100","author":"Iacoboni","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2025.01.001_bib0006","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3390\/jcm11061522","article-title":"Value of CT-textural features and volume-based PET parameters in comparison to serologic markers for response prediction in patients with diffuse large B-cell lymphoma undergoing CD19-CAR-T cell therapy","volume":"11","author":"Reinert","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtct.2025.01.001_bib0007","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/bloodadvances.2021005807","article-title":"Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma","volume":"6","author":"Kuhnl","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.01.001_bib0008","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.01.001_bib0009","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/bloodadvances.2020003959","article-title":"Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting","volume":"5","author":"Ayuk","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.01.001_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.01.001_bib0011","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","article-title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL","volume":"4","author":"Awasthi","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.01.001_bib0012","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1182\/blood-2022-169212","article-title":"Monitoring the in-vivo expansion and persistence of CAR-T cells as a tool to help decision making in patients with aggressive B-cell lymphoma","volume":"140","author":"F\u00fcrst","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.01.001_bib0013","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.omtm.2019.12.018","article-title":"Digital PCR assays for precise quantification of CD19 CAR-T cells after treatment with axicabtagene ciloleucel","volume":"16","author":"Fehse","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtct.2025.01.001_bib0014","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3389\/fimmu.2020.01770","article-title":"The chimeric antigen receptor detection toolkit","volume":"11","author":"Hu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2025.01.001_bib0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/cyto.a.24676","article-title":"Monitoring anti-CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction","volume":"103","author":"Cheng","year":"2023","journal-title":"Cytometry A"},{"key":"10.1016\/j.jtct.2025.01.001_bib0016","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/cyto.b.21941","article-title":"Monitoring CAR T-cells using flow cytometry","volume":"100","author":"Demaret","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.jtct.2025.01.001_bib0017","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2025.01.001_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.830773","article-title":"Monitoring of circulating CAR T cells: validation of a flow cytometric assay, cellular kinetics, and phenotype analysis following tisagenlecleucel","volume":"13","author":"Peinelt","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2025.01.001_bib0019","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1182\/bloodadvances.2023010364","article-title":"Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R\/R DLBCL","volume":"7","author":"Blumenberg","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.01.001_bib0020","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.01.001_bib0021","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials."},{"key":"10.1016\/j.jtct.2025.01.001_bib0022","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.01.001_bib0023","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/hematology.2023000438","article-title":"Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas","volume":"2023","author":"Major","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2025.01.001_bib0024","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/bloodadvances.2022009426","article-title":"Circulating tumor DNA adds specificity to PET following axicabtagene ciloleucel in large B-cell lymphoma","volume":"7","author":"Dean","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.01.001_bib0025","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1182\/blood-2021-152309","article-title":"Tisagenlecleucel and axicabtagene ciloleucel expansion kinetics and CAR T cell attributes in the infusion products are early predictors of clinical efficacy","volume":"138","author":"Carniti","year":"2021","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725000028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725000028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:37:54Z","timestamp":1772325474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725000028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2666636725000028"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.01.001","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced Chimeric Antigen Receptor T Cell Expansion Postinfusion Is Associated with Poor Survival in Patients with Large B Cell Lymphoma after Two or More Therapies","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}